Cargando…
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Reoccurring/high-risk neuroblastoma (NB) tumors have the enrichment of non-RAS/RAF mutations along the mitogen-activated protein kinase (MAPK) signaling pathway, suggesting that activation of MEK/ERK is critical for their survival. However, based on preclinical data, MEK inhibitors are unlikely to b...
Autores principales: | Cai, Jinyang, Jacob, Sheeba, Kurupi, Richard, Dalton, Krista M., Coon, Colin, Greninger, Patricia, Egan, Regina K., Stein, Giovanna T., Murchie, Ellen, McClanaghan, Joseph, Adachi, Yuta, Hirade, Kentaro, Dozmorov, Mikhail, Glod, John, Boikos, Sosipatros A., Ebi, Hiromichi, Hao, Huaixiang, Caponigro, Giordano, Benes, Cyril H., Faber, Anthony C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353975/ https://www.ncbi.nlm.nih.gov/pubmed/35905710 http://dx.doi.org/10.1016/j.celrep.2022.111095 |
Ejemplares similares
-
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
por: Kurupi, Richard, et al.
Publicado: (2022) -
Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin
por: Yoo, Byunghee, et al.
Publicado: (2018) -
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021) -
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
por: Fairchild, Carter K., et al.
Publicado: (2021) -
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)